A comparison of portal venous versus systemic venous drainage in pancreas transplantation.


Journal

HPB : the official journal of the International Hepato Pancreato Biliary Association
ISSN: 1477-2574
Titre abrégé: HPB (Oxford)
Pays: England
ID NLM: 100900921

Informations de publication

Date de publication:
02 2019
Historique:
received: 26 12 2017
revised: 05 07 2018
accepted: 12 07 2018
pubmed: 1 9 2018
medline: 9 4 2020
entrez: 1 9 2018
Statut: ppublish

Résumé

The decision to utilize portal or systemic venous drainage in pancreas transplantation is surgeon- and center-dependent. Information regarding the superior method is based on single-center reports and animal models. UNOS data on adults receiving pancreas and kidney-pancreas transplants from 1987 to 2016 were analyzed (n = 29 078). The groups analyzed were: systemic venous pancreas graft drainage (SVD, n = 24 512) or portal venous pancreas graft drainage (PVD, n = 4566). A Cox proportional hazard model compared patient and allograft survival between groups. No statistically significant differences were observed for patient and allograft survival at 1, 3, 5, 10, or 15 years post-transplant at each time interval and cumulatively (patient - HR:1.041; 95% CI:0.989-1.095; allograft - HR:0.951; 95% CI:0.881-1.027). PVD reduced the risk of death by 22.0% (P = 0.017) compared to SVD for patients undergoing pancreas after kidney transplant (PAK); no statistically significant difference was found for patients undergoing other types of transplants. There is no significant clinical difference in patient or allograft survival between PVD and SVD in pancreas transplantation for the majority of patients. For the subgroup of PAK, PVD was associated with decreased mortality. For individual surgeons, center and patient scenarios should dictate which technique is performed.

Sections du résumé

BACKGROUND
The decision to utilize portal or systemic venous drainage in pancreas transplantation is surgeon- and center-dependent. Information regarding the superior method is based on single-center reports and animal models.
METHODS
UNOS data on adults receiving pancreas and kidney-pancreas transplants from 1987 to 2016 were analyzed (n = 29 078). The groups analyzed were: systemic venous pancreas graft drainage (SVD, n = 24 512) or portal venous pancreas graft drainage (PVD, n = 4566). A Cox proportional hazard model compared patient and allograft survival between groups.
RESULTS
No statistically significant differences were observed for patient and allograft survival at 1, 3, 5, 10, or 15 years post-transplant at each time interval and cumulatively (patient - HR:1.041; 95% CI:0.989-1.095; allograft - HR:0.951; 95% CI:0.881-1.027). PVD reduced the risk of death by 22.0% (P = 0.017) compared to SVD for patients undergoing pancreas after kidney transplant (PAK); no statistically significant difference was found for patients undergoing other types of transplants.
CONCLUSION
There is no significant clinical difference in patient or allograft survival between PVD and SVD in pancreas transplantation for the majority of patients. For the subgroup of PAK, PVD was associated with decreased mortality. For individual surgeons, center and patient scenarios should dictate which technique is performed.

Identifiants

pubmed: 30166090
pii: S1365-182X(18)32705-9
doi: 10.1016/j.hpb.2018.07.018
pii:
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

195-203

Informations de copyright

Copyright © 2018 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Auteurs

Eric Siskind (E)

Inova Fairfax Medical Campus, Department of Surgery, Inova Kidney and Pancreas Transplant Program, 3300 Gallows Road, Falls Church, VA, 22042, USA. Electronic address: Eric.Siskind@inova.org.

Leo Amodu (L)

Northwell Health System, Transplant Center, 300 Community Drive, Manhasset, NY, 11030, USA.

Chang Liu (C)

Inova Fairfax Medical Campus, Department of Surgery, Inova Kidney and Pancreas Transplant Program, 3300 Gallows Road, Falls Church, VA, 22042, USA.

Meredith Akerman (M)

Northwell Health System, Transplant Center, 300 Community Drive, Manhasset, NY, 11030, USA.

Joshua Stodghill (J)

Inova Fairfax Medical Campus, Department of Surgery, Inova Kidney and Pancreas Transplant Program, 3300 Gallows Road, Falls Church, VA, 22042, USA.

Ravinder Wali (R)

Inova Fairfax Medical Campus, Department of Surgery, Inova Kidney and Pancreas Transplant Program, 3300 Gallows Road, Falls Church, VA, 22042, USA.

James Piper (J)

Inova Fairfax Medical Campus, Department of Surgery, Inova Kidney and Pancreas Transplant Program, 3300 Gallows Road, Falls Church, VA, 22042, USA.

Johann Jonsson (J)

Inova Fairfax Medical Campus, Department of Surgery, Inova Kidney and Pancreas Transplant Program, 3300 Gallows Road, Falls Church, VA, 22042, USA.

Ernesto Molmenti (E)

Northwell Health System, Transplant Center, 300 Community Drive, Manhasset, NY, 11030, USA.

Jorge Ortiz (J)

University of Toledo Medical Center Kidney Transplant Program, 3000 Arlington Avenue, Toledo, OH, 43614, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH